Mẹo về How many days of acquiring or discovering a significant financial interest is the investigator required to submit an updated disclosure? Mới Nhất
Hà Quang Phong đang tìm kiếm từ khóa How many days of acquiring or discovering a significant financial interest is the investigator required to submit an updated disclosure? được Update vào lúc : 2022-09-05 01:12:02 . Với phương châm chia sẻ Bí quyết Hướng dẫn trong nội dung bài viết một cách Chi Tiết Mới Nhất. Nếu sau khi Read tài liệu vẫn ko hiểu thì hoàn toàn có thể lại Comment ở cuối bài để Tác giả lý giải và hướng dẫn lại nha.
Purpose: As an institution involved in Public Health Service (PHS) funded research, Sigray strives to promote objectivity in research. This Financial Conflict of Interest (FCOI) Policy has been established to prevent bias resulting from financial conflicts of interest in the design, conduct and reporting of research funded under PHS grants. Sigray’s FCOI policy applies to all investigators who participate in PHS funded research. Regulations governing FCOI can be found under 42 CFR Part 50 Subpart F.
Nội dung chính- How many days of acquiring or discovering a significant financial interest is the investigator?Which of the following is considered to be a significant financial interest?What is true regarding the US Public Health Service and its approach to the disclosure of significant financial interests?What is the value amount threshold for disclosing an outside activity or interest?
The principal investigator(s) and participants who are responsible for the design, conduct and reporting of research funded by the PHS must disclose any financial conflict of interest. A financial conflict of interest may exist if the investigator, or the investigators’ spouse and dependents hold a significant financial interest in the following:
- Ownership of stock, equity, or other financial interest in a company/entity which has products that might be used in or benefit from or harmed by the results of the projectEmployment, office or directorship in any company/entity involved or potentially involvedPersonal compensation from any company/entity involved or
potentially involved Consulting/advisory arrangements with any company/entity involved or potentially involved Involvement with grants, contracts, research, training or other support (restricted or unrestricted) from any company/entity involved or potentially involvedTravel grants to attend educational symposia provided by any company/entity involved or potentially involved Intellectual property rights (i.e. copyright, patent, trademark) related
to the activities of the projectRelationship with a company/entity that may affect academic advancement or status
Disclosure, Training, Review and Monitoring:
Prior to starting work on a PHS funded grant, all participants will be provided a copy of this policy and will undergo FCOI training least once every 4 years. Investigators must also provide the following information in a Disclosure Form, which must be submitted to Sylvia Lewis, who is the designated Institutional Official (IO) for FCOI policy.
Name of the individual(s) Name of the entity with which the investigator(s) has a financial conflict of interestThe nature of the significant financial interestThe value of the financial interestDescription of how the financial interest relates to the research projectThis information must be disclosed prior to the funding of a project/grant and should be disclosed prior to beginning funding solicitation.
The IO will review disclosure forms prior to the research start date to determine whether there is a Significant Financial Interest (SFI) as described in 42 CFR Part 50 Subpart F Section 50.603(1), and whether the SFI is related to the PHS funded research. If the IO determines the existence of an FCOI, the IO will implement appropriate measures to restrict or eliminate the FCOI.
Examples of conditions or restrictions that might be imposed to manage a financial conflict of interest include, but are not limited to:
1) Public disclosure of financial conflicts of interest (e.g., when presenting or publishing the research);
2) For research projects involving human subjects research, disclosure of financial conflicts of interest directly to participants;
3) Appointment of an independent monitor capable of taking measures to protect the design, conduct, and reporting of the research against bias resulting from the
financial conflict of interest;
4) Modification of the research plan;
5) Change of personnel or personnel responsibilities, or disqualification of personnel from participation in all or a portion of the research;
6) Reduction or elimination of the financial interest (e.g., sale of an equity interest); or
7) Severance of relationships that create financial conflicts.
If a new SFI develops during the research period, or if the Investigator did not previously disclose an existing SFI prior to the research start date, the Investigator must submit a disclosure form within 30 days of acquiring or discovering a new SFI. The IO will review the disclosure form and make an FCOI determination within 60 days of receipt of the form.
The IO will periodically monitor investigator compliance under this policy throughout the research period. Questions or concerns regarding this policy should be directed to the IO
Reporting Requirements:
If an investigator is found to have a financial conflict of interest, the IO will submit an FCOI report to the PHS Awarding Component prior to expending funds for the PHS research. If an FCOI is found during the research period, the IO will submit an FCOI report and a management plan to the PHS Awarding Component within 60 days of identifying the FCOI. The FCOI report will include:
(i) Project number;
(ii) PD/PI or Contact PD/PI if a multiple PD/PI model is used;
(iii) Name of the
Investigator with the financial conflict of interest;
(iv) Name of the entity with which the Investigator has a financial conflict of interest;
(v) Nature of the financial interest (e.g., equity, consulting fee, travel reimbursement, honorarium);
(vi) Value of the financial interest (dollar ranges are permissible: $0-$4,999; $5,000-$9,999; $10,000-$19,999; amounts between $20,000-$100,000 by increments of $20,000; amounts above $100,000 by increments of $50,000), or a statement that the
interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value;
(vii) A description of how the financial interest relates to the PHS-funded research and the basis for the Institution’s determination that the financial interest conflicts with such research; and
(viii) A description of the key elements of the Institution’s management plan, including:
(A) Role and principal duties of the conflicted
Investigator in the research project;
(B) Conditions of the management plan;
(C) How the management plan is designed to safeguard objectivity in the research project;
(D) Confirmation of the Investigator’s agreement to the management plan;
(E) How the management plan will be monitored to ensure Investigator compliance; and
(F) Other information as needed.
If an FCOI report is submitted, the IO will provide an annual FCOI report to the PHS Awarding Component that addresses the status of the financial conflict of interest and any changes to the management plan for the duration of the PHS-funded research project.
If an FCOI is not identified or managed in a timely manner, the IO will complete a retrospective review of the investigator’s activities and the PHS funded research within 120 days of the discovery of noncompliance to determine whether the design, conduct, or reporting of the PHS funded research has been tainted by bias during the period of noncompliance.
The review will be documented with the following information:
(1) Project number;
(2) Project title;
(3) PD/PI or contact PD/PI if a multiple PD/PI model is used;
(4) Name of the Investigator with the FCOI;
(5) Name of the entity with which the Investigator has a financial conflict of interest;
(6) Reason(s) for the retrospective review;
(7) Detailed methodology used for the
retrospective review (e.g., methodology of the review process, composition of the review panel, documents reviewed);
(8) Findings of the review; and
(9) Conclusions of the review.
If bias is found, the IO will notify the PHS Awarding Component and submit a mitigation report that contains the information found during the review.
Maintenance of Records:
FCOI disclosures and reports will be maintained for a period of 3 years after the end of the research period, or from other dates as specified in 45 CFR 75.361 where applicable.
Enforcement, Remedies and Noncompliance:
Violations of this policy will be fully investigated. Individual(s) found in violation of this policy will be removed from the project and will be subject to disciplinary action including but not limited to administrative leave, and/or termination.
Under certain circumstances, if the HHS determines that an FCOI resulted in bias in the PHS funded research, the investigator with the financial conflict of interest may be required to disclose the FCOI each public presentation of the results.
Subrecipient Requirements:
FCOI regulations apply to subcontractors used in any PHS funded research. Subcontractors must have their own FCOI policy or use Sigray’s policy if none exists. The contracting agreement should certify that the subcontractor shall comply with FCOI regulations. The agreement should also specify the time period to submit disclosure forms and FCOI reports to Sigray.
Public Accessibility:
A copy of this policy can be found on Sigray’s website www.sigray.com. FCOI requests can be made in writing to Sigray Inc. 5750 Imhoff Drive, Suite I, Concord, California.
If an SFI was 1) disclosed and is still held by the Investigator, 2) the SFI is related to PHS funded research, and 3) the SFI is determined to be a financial conflict of interest, Sigray will issue a written response to your FCOI request within 5 business days of the request.
The information will include the Investigator’s name; the Investigator’s title and role with respect to the research project; the name of the entity in which the significant financial interest is held; the nature of the significant financial interest; and the approximate dollar value of the significant financial interest (dollar ranges are permissible: $0-$4,999; $5,000-$9,999; $10,000-$19,999; amounts between $20,000-$100,000 by increments of $20,000; amounts above $100,000 by increments of $50,000), or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Sigray will note in its written response that the information provided is current as of the date of the correspondence and is subject to updates, on least an annual basis and within 60 days of the identification of a new financial conflict of interest, which should be requested subsequently by the requestor.
How many days of acquiring or discovering a significant financial interest is the investigator?
The institution must also require each Investigator who is participating in NIH-funded research to submit an updated disclosure of SFIs within thirty days of discovering or acquiring a new SFI. This discovery or acquirement may be due to marriage, purchase, or inheritance, for example.Which of the following is considered to be a significant financial interest?
A financial interest is deemed to be significant if: the aggregate value of Remuneration and Equity Interests in lieu of payment received from a US or foreign publicly traded entity during the 12 month period preceding the disclosure exceeds $5,000; or.What is true regarding the US Public Health Service and its approach to the disclosure of significant financial interests?
Which of the following is true regarding the PHS's approach to the disclosure of significant financial interests? Any equity in a non-publicly traded company must be disclosed. According to the PHS regulations, investigators are required to disclose travel sponsored or reimbursed by: A publicly traded company.What is the value amount threshold for disclosing an outside activity or interest?
CFR Part 50, Subpart F (the "FCOI Regulations"). twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000. Tải thêm tài liệu liên quan đến nội dung bài viết How many days of acquiring or discovering a significant financial interest is the investigator required to submit an updated disclosure?